Compare Fortinet Inc (FTNT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs GeneDx Holdings Corp — how do they compare? Fortinet Inc trades at $162.56 (market cap $120.53B), while GeneDx Holdings Corp trades at $64.79 (market cap $1.96B). The key difference: Fortinet Inc is far larger — about 61.5× GeneDx Holdings Corp's market cap, and Fortinet Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| FTNT | WGS | |
|---|---|---|
Market Cap | $120.53B | $1.96B |
Sector | Technology | Technology |
52-Week High | $166.83 | $167.51 |
52-Week Low | $74.39 | $34.51 |
Enterprise Value | $117.73B | $1.96B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fortinet (FTNT) trades at $166.83, up 3.87% today, with a bullish technical signal from moving averages and strong quarterly earnings beats. Revenue grew to $6.80B in 2025, with a net income margin of 27.49%, though valuation ratios like P/E of 63.76 and P/S of 17.5 appear elevated. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with the company expanding its FortiEndpoint platform for AI security.
The outlook is positive due to robust earnings performance and sector tailwinds, but high valuations and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, yet the consensus price target of $123.16 suggests caution relative to the current price, indicating potential overvaluation concerns amid growth optimism.
GeneDx Holdings Corp. (WGS) trades at $65.785, up 5.37% today, but faces a bearish technical signal with the stock near resistance at $65. The company shows mixed fundamentals with strong revenue growth to $427.54M in 2025 but a net loss of -$21.02M, while analyst consensus remains bullish with a $75.40 price target. Recent news highlights multiple class-action lawsuits alleging securities fraud tied to a 49% stock decline and acquisition underperformance, creating significant investor uncertainty.
The outlook is highly conflicted: strong analyst buy ratings and recent earnings beats contrast with deepening losses, negative cash flow projections for 2026, and legal overhangs. Key risks include litigation outcomes, profitability challenges, and execution missteps, but the stock offers potential upside if the company can stabilize margins and resolve legal issues amid high institutional skepticism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
